Venetoclax is a treatment option in pediatric r/r AML and ALL, especially when specific genomic profiles are present (e.g., hypodiploid, KMT2A-, and TCF3-rearranged ALL) [2]. The gene discussed is TCF3; the disease is acute lymphoblastic leukemia.